Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278864

—

32d36782-3e59-5ab5-9a8e-1203a3e808d2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.630
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
  • ANGIOGENESIS+0.440
  • INTERFERON_GAMMA_RESPONSE+0.440
  • UNFOLDED_PROTEIN_RESPONSE+0.360
  • HEDGEHOG_SIGNALING+0.330
  • APICAL_JUNCTION+0.270
  • UV_RESPONSE_DN+0.260
  • MYC_TARGETS_V2+0.240
  • COAGULATION+0.230

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.430
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
  • BILE_ACID_METABOLISM-0.230
  • ADIPOGENESIS-0.220
  • SPERMATOGENESIS-0.220
  • NOTCH_SIGNALING-0.190
  • FATTY_ACID_METABOLISM-0.180
  • TNFA_SIGNALING_VIA_NFKB-0.150
  • E2F_TARGETS-0.140
  • KRAS_SIGNALING_DN-0.120

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8943046
bladder-landscape@3
——0.730
2TCGA-XF-AAMT-01A-11R-A42T-07
bladder-landscape@3
——0.724
3TCGA-DQ-7592-01A-11R-2081-07
head-neck@1
——0.711
4s0122188
melanoma-umap@29
——0.705
5TCGA-56-6545-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.691
6TCGA-AN-A0FD-01A-11R-A034-07
breast-umap@18
—C0.686
7TCGA-XF-AAMW-01A-11R-A42T-07
bladder-landscape@3
——0.686
8TCGA-CN-5366-01A-01R-1436-07
head-neck@1
——0.683
9TCGA-A8-A07I-01A-11R-A00Z-07
breast-umap@18
—C0.681
10TCGA-CQ-A4C7-01A-11R-A24Z-07
head-neck@1
——0.675

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.630Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.510Inavolisib— uncovered
ANGIOGENESIS0.440Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.440Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.360Idelalisib— uncovered
HEDGEHOG_SIGNALING0.330Inavolisib— uncovered
APICAL_JUNCTION0.270Inavolisib— uncovered
UV_RESPONSE_DN0.260Inavolisib— uncovered
MYC_TARGETS_V20.240Idelalisib— uncovered
COAGULATION0.230Binimetinib— uncovered
APICAL_SURFACE0.220Temsirolimus— uncovered
PROTEIN_SECRETION0.220Remibrutinib— uncovered
HYPOXIA0.180Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.150Remibrutinib— uncovered
COMPLEMENT0.130Inavolisib— uncovered
P53_PATHWAY0.130Idelalisib— uncovered
TGF_BETA_SIGNALING0.130Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.120Inavolisib— uncovered
MITOTIC_SPINDLE0.120Inavolisib— uncovered
MYC_TARGETS_V10.110Inavolisib— uncovered